CD4 Antibody Blocking Peptide
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-19371PEP
Key Product Details
Conjugate
Unconjugated
Applications
Antibody Competition
Product Specifications
Description
Application Notes
This peptide is useful as a blocking peptide for NBP1-19371. For further blocking peptide related protocol, click here.
Specificity
This peptide is specific for NBP1-19371 only.
Protein / Peptide Type
Antibody Blocking Peptide
Formulation, Preparation and Storage
NBP1-19371PEP
| Formulation | Peptide dissolved in dH20. Contains no BSA. |
| Preservative | No Preservative |
| Concentration | 1 mg/ml |
| Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Store at -80C. Avoid freeze-thaw cycles. |
Background: CD4
Given its critical role in T cell development, CD4 also has diverse immunology-related functions. CD4 acts as a coreceptor with the T-cell receptor (TCR) during T cell activation and thymic differentiation by binding directly to major histocompatibility complex (MHC) class II antigens and associating with the protein tyrosine kinase, Lck (4). This interaction contributes to the formation of the immunological synapse (5). Defects in antigen presentation cause dysfunction of CD4+ T cells and the almost complete loss of MHC II expression on B cells in peripheral blood, as observed in severe combined immunodeficiency (SCID) (6). CD4 also functions as a receptor for the human immunodeficiency virus (HIV) by binding to gp120, the envelope glycoprotein of HIV-1. It has been shown that the V-like domains are critical for binding to gp120 (7). In immune mediated and infectious diseases of the central nervous system, CD4 functions as an indirect mediator of neuronal damage (8).
References
1. Omri, B., Crisanti, P., Alliot, F., Marty, M., Rutin, J., Levallois, C., . . . Pessac, B. (1994). CD4 expression in neurons of the central nervous system. International Immunology, 6(3), 377-385. doi:10.1093/intimm/6.3.377
2. Wan, Y. Y., & Flavell, R. A. (2009). How diverse-CD4 effector T cells and their functions. Journal of Molecular Cell Biology, 1(1), 20-36. doi:10.1093/jmcb/mjp001
3. Wu, H., Myszka, D. G., Tendian, S. W., Brouillette, C. G., Sweet, R. W., Chaiken, I. M., & Hendrickson, W. A. (1996). Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding. Proceedings of the National Academy of Sciences, 93(26), 15030-15035. doi:10.1073/pnas.93.26.15030
4. Doyle, C., & Strominger, J. L. (1987). Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature, 330, 256-259. doi:10.1038/330256a0
5. Vignali, D. A. (2010). CD4 on the road to coreceptor status. The Journal of Immunology, 184(11), 5933-5934. doi:10.4049/jimmunol.1090037
6. Tasher, D., & Dalal, I. (2012). The genetic basis of severe combined immunodeficiency and its variants. The Application of Clinical Genetics, 5, 67-80. doi:10.2147/tacg.s18693
7. Arthos, J., Deen, K. C., Chaikin, M. A., Fornwald, J. A., Sathe, G., Sattentau, Q. J., . . . Sweet, R. W. (1989). Identification of the residues in human CD4 critical for the binding of HIV. Cell, 57(3), 469-481. doi:10.1016/0092-8674(89)90922-7
8. Buttini, M., Westland, C. E., Masliah, E., Yafeh, A. M., Wyss-Coray, T., Mucke, L. (1998). Novel role of human cd4 molecule identified in neurodegeneration. Nature Medicine, 4(4), 441-446. doi:10.1038/nm0498-441
Alternate Names
CD4
Gene Symbol
CD4
Additional CD4 Products
Product Documents for CD4 Antibody Blocking Peptide
Product Specific Notices for CD4 Antibody Blocking Peptide
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...